European Union & Gilead Sciences

European Union: The European Union has provided critical medical supplies, including masks, gloves, boots, and medications, to aid the Ebola response in the Democratic Republic of the Congo.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

European Union: The European Union considers the risk to its general public very low but has begun coordinating laboratory preparedness and traveler guidance through its Health Security Committee.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

European Union: The European Union is mentioned as a potential location for treating US citizens exposed to Ebola, though the focus is primarily on Kenya.

Gilead Sciences: Gilead Sciences' antiviral remdesivir is mentioned as a potential treatment to be used at the quarantine facility, indicating its role in the medical response to Ebola.

European Union: A spokesperson for the European Union>>> stated that the risk of an Ebola outbreak in Europe is 'very low', indicating monitoring of the situation but no immediate alarm for the region.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.